

ARTIFICIAL INTELLIGENCE IN HPV-RELATED PRECANCERS AND CANCERS

MONDAY, MARCH 17

ALFÂNDEGA PORTO AUDITORIUM | 8.00 • 12.30

HONORARY CHAIRS



Eduardo Franco
Canada



Joseph Monsonego
France

MODERATORS



Nicolas Wentzensen
US



Sreenath Madathil
Canada

SCIENTIFIC COMMITTEE

Basu P. _____ France

Monsonego J. _____ France

Franco E. _____ Canada

Rydzewski N. R. _____ United States

Grabe N. _____ Germany

Schmidt J. _____ Germany

Madathil S. _____ Canada

Wentzensen N. _____ United States

Full program details on **next page**

ARTIFICIAL INTELLIGENCE IN HPV-RELATED PRECANCERS AND CANCERS

LEVERAGING ARTIFICIAL INTELLIGENCE IN SCREENING AND MANAGEMENT OF HPV-RELATED PRECANCERS AND CANCERS

Join us for an insightful session on Artificial Intelligence in HPV-related precancers and cancers, where we explore the growing role of AI in transforming cancer screening, diagnosis, and management.

This session will cover the latest AI technologies in cervical cancer screening, trustworthy AI in clinical practice, and machine learning models for predicting HPV-driven cancer progression. Experts will share real-world applications, discuss challenges, and highlight AI-enhanced tools like colposcopy. Engage in dynamic discussions on AI's future in healthcare and collaborative opportunities.

Don't miss this opportunity to understand how AI is reshaping the landscape of oncology.

AI 01 • PART I

8.00 • 10.15

AI 01-1 • Opening introduction to AI in oncology	Rydzewski N. R. (US)
AI 01-2 • AI in cervical cancer screening: Current advances and future directions	Basu P. (France)
AI 01-3 • AI-enhanced colposcopy: Improving interpretability and trustworthiness via natural language explanations	Madathil S. (Canada)
AI 01-4 • Developing robust and reliable AI algorithms for clinical applications: The example of Cytoreader	Grabe N. (Germany)
AI 01-5 • How to move AI-based tests into clinical practice	Wentzensen N. (US)
AI 01-6 • AI regulation in healthcare within the European Union	Schmidt J. (Germany)
Panel discussion and closing remarks: The future of AI in HPV-related disease management	
Discussion and Q&A	

AI 02 • PART II – FREE COMMUNICATIONS

10.45 • 12.30

AI 02-1 • Artificial intelligence as a potential tool to boost cervical cancer screening programs using individualized risk prediction	Garcia-Serrano A. (Sweden)
AI 02-2 • A prediction model for high-grade cervical lesions using machine learning in Swedish women	Deng Y. (Sweden)
AI 02-3 • New method for hrHPV screening using the deepFM-RF model: A multicenter, multi-ethnic validation study	Hu Z. (China)
AI 02-4 • Deep learning and HPV pleomorphic multiorgan induced lesions: Automated detection and differentiation of cervical and anal squamous cancers precursors – a multicentric study	Mascarenhas M. (Portugal)
AI 02-5 • Automated evaluation of p16/ki67 dual stain cytology as an artificial intelligence-based biomarker for detection of cervical intraepithelial neoplasia of grade 2 or worse in HPV-positive women in cervical cancer screening	Gustafson L. W. (Denmark)
AI 02-6 • The IMP diagnostics Roadmap to Implement the Genius™ digital diagnostics system in real-life clinical practice	Montezuma D. (Portugal)
AI 02-7 • Effect of an artificial intelligence-guided colposcopy for detection of cervical precancer and cancer: A multicentre, randomized, crossover trial	Xue P. (China)
AI 02-8 • Large language models in cervical cancer control education: Comparing ChatGPT and Baichuan4 to human-generated multiple choice questions	Ma J. (China)
AI 02-9 • Artificial intelligence based screening by colposcopy: An image catalogue to build machine learning algorithms for female genital schistosomiasis and gynaecological disorders	Fusco D. (Germany)
AI 02-10 • County-level HPV vaccination rates: Analysis of 10 million publicly-insured US adolescents	Sonawane K. (US)